Aligned Genetics Inc (238120) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Aligned Genetics Inc stock KRW 3,492, price KRW 2,650, upside +31.8%, quality 50 out of 100. Rating: undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 2,435 KRW – 6,225 KRW · fair‑value band 2,619 KRW – 4,365 KRW · the 2,650 KRW price screens below the 3,492 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Aligned Genetics in your weekly email
Every Wednesday you see whether Aligned Genetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name.
Show moreShow less
The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.
Stock analysis
Aligned Genetics Inc (238120) currently trades at 2,650 KRW, while our model-based Fair Value estimate is 3,492 KRW, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 4,087 KRW per share, and 7 of the 14 models we run sit above the 2,650 KRW price.
Bear case: the Economic Profit group reads lowest at 2,140 KRW, and 7 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 2,619 KRW (bear) to 4,365 KRW (bull), the price of 2,650 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Aligned Genetics Inc reported revenue of 16.0B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +8.0%/yr. Reported net income was 2.9B KRW in FY2025, compounding −14.9%/yr from FY2021.
Key figures
Market cap 37.3B KRW (≈ $27.5M) Micro · P/E ratio 8.1 · P/S ratio 2.31 · EPS (TTM) 327.53 KRW · Net margin 28.7% · Return on equity 12.6% · Return on assets (EBIT) 6.5% (5-year average) · Operating margin 14.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 32%, 238120 screens cheaper than that median.
Fair Value models
Bear2,619 KRWFair Value 3,492 KRWBull4,365 KRW
Price 2,650 KRW · Upside +31.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (280.87 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Start year 2020 (pandemic). Over 10 years: +14.6% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → 15%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+31.8% · Top 25%
Profitability
Return on equity (12 months)12.6% · Top 25%
Return on assets5.0% · Above median
Net margin (12 months)28.7% · Top 25%
Operating margin (12 months)14.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.9% · Above median
Balance sheet
Debt / equity0.32× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Aligned Genetics Inc (238120) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 3,492 KRW versus a price of 2,650 KRW, about +32% upside (undervalued).
What is the fair value of 238120?
Our model-based fair value for Aligned Genetics Inc is 3,492 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 2,650 KRW.
What is the quality score of 238120?
Aligned Genetics Inc has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aligned Genetics Inc (238120)?
Our model-based price target is the fair value of 3,492 KRW (as of Nov 3, 2026) from 14 valuation models. Cautious scenario 2,619 KRW, optimistic scenario 4,365 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Aligned Genetics Inc stock forecast for 2026?
Our models put fair value at 3,492 KRW, about +32% upside versus a price of 2,650 KRW (undervalued). Cautious scenario 2,619 KRW, optimistic scenario 4,365 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aligned Genetics Inc (238120)?
Aligned Genetics Inc reported trailing-twelve-month revenue of about 16.2B KRW (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Aligned Genetics Inc (238120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aligned Genetics Inc it is 3,492 KRW per share (as of Nov 3, 2026), against a price of 2,650 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Aligned Genetics Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 238120 trades below its calculated fair value: price 2,650 KRW, fair value 3,492 KRW, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 238120?
No. The price is what the market pays today (2,650 KRW); the fair value is what the company's own numbers justify (3,492 KRW). For Aligned Genetics Inc the two are 842.32 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aligned Genetics Inc worth?
The market values Aligned Genetics Inc at about 37.3B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 2,650 KRW; our models calculate a fair value of 3,492 KRW per share.
What do the bullish and bearish scenarios say about 238120?
Our models span a range for Aligned Genetics Inc: cautious scenario 2,619 KRW, base 3,492 KRW, optimistic 4,365 KRW per share (as of Nov 3, 2026, price 2,650 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 238120?
Aligned Genetics Inc trades at a price-to-earnings ratio of 8.1 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3,492 KRW is built from several models across several years. Other multiples: P/B 1.0, P/S 2.3, EV/EBITDA 10.7.
How solid is the balance sheet of Aligned Genetics Inc (238120)?
Balance-sheet figures for Aligned Genetics Inc (as of Nov 3, 2026): return on equity 12.6%, debt of 0.32 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 238120 from its 52-week high?
Aligned Genetics Inc trades at 2,650 KRW, about 56% below its 52-week high of 6,050 KRW and 9% above the low of 2,435 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3,492 KRW is for.
Which stocks are comparable to Aligned Genetics Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aligned Genetics Inc stock attractive at the current price?
The data as of Nov 3, 2026: price 2,650 KRW, calculated fair value 3,492 KRW (+32%), Quality Score 50/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 238120 calculated?
We run Aligned Genetics Inc through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 3,492 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Aligned Genetics Inc currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aligned Genetics Inc (238120)?
The closing price on Nov 6, 2026 was 2,650 KRW. Our model-based fair value is 3,492 KRW, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aligned Genetics Inc right now?
Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Aligned Genetics Inc
How large is the market capitalisation of Aligned Genetics Inc (238120)?
The market capitalisation of Aligned Genetics Inc is 37.3B KRW (≈ $27.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aligned Genetics Inc (238120)?
The price-to-sales ratio of Aligned Genetics Inc is 2.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aligned Genetics Inc (238120)?
Earnings per share at Aligned Genetics Inc are 327.53 KRW (price ÷ EPS = P/E 8.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aligned Genetics Inc (238120)?
The net margin of Aligned Genetics Inc is 28.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aligned Genetics Inc (238120)?
The return on equity (ROE) of Aligned Genetics Inc is 12.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aligned Genetics Inc (238120)?
On an EBIT basis the return on assets of Aligned Genetics Inc is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aligned Genetics Inc (238120)?
The operating margin of Aligned Genetics Inc is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aligned Genetics Inc (238120)?
Revenue at Aligned Genetics Inc is growing +10.9% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aligned Genetics Inc (238120)?
Earnings per share at Aligned Genetics Inc are growing −23.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aligned Genetics Inc (238120) generate?
The free cash flow of Aligned Genetics Inc is −9.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Aligned Genetics Inc in the live analysis
One click puts Aligned Genetics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026